文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

PD-1抑制剂治疗黑色素瘤脑转移中局部治疗使用频繁,凸显多学科管理必要性

Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-08-31

该研究基于前瞻性2期试验NCT02085070的23例黑色素瘤脑转移患者,分析接受帕博利珠单抗治疗期间局部治疗的使用情况。结果显示57%患者在研究前或研究期间接受局部治疗,仅9%患者2年内无需局部治疗。结论认为局部治疗在免疫治疗时代仍具重要地位,需多学科团队参与决策。

要点

  • 57%黑色素瘤脑转移患者在接受帕博利珠单抗前或期间需局部治疗。
  • 仅9%患者2年内无需局部治疗,35%因快速进展未能接受局部治疗。
  • 应通过连续脑影像监测并由多学科团队参与决策。

核心结论

  • 局部治疗在接受免疫治疗的黑色素瘤脑转移患者管理中仍发挥重要作用。
  • 此类患者应通过连续脑影像密切监测,并由多学科团队参与临床决策以确保神经系统安全。

研究设计与样本

  • 研究为前瞻性2期试验NCT02085070的二次分析,纳入23例接受帕博利珠单抗治疗的黑色素瘤脑转移患者。
  • 入组患者至少有一个未治疗或进展的脑转移灶,大小5至20毫米,无相关神经系统症状。

主要发现

  • 23例患者中13例(57%)在研究前或研究期间接受了局部治疗。
  • 4例因病灶大小或位于敏感区域在研究前接受局部治疗,6例因肿瘤生长、出血或放射性坏死/囊性变在研究期间接受局部治疗,3例在研究前和研究期间均接受局部治疗。
  • 未接受局部治疗的10例患者中,8例(35%)因疾病快速进展未能接受局部治疗,仅2例(9%)在未需任何局部治疗的情况下生存2年。

临床怎么用

  • 对接受免疫治疗的黑色素瘤脑转移患者应进行连续脑影像监测。
  • 临床决策应由多学科团队参与,以确保患者神经系统安全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An increasing number of clinical trials are studying immunotherapy for the treatment of brain metastases. The role of local therapy in this setting has not been well described. METHODS AND MATERIALS: Twenty-three melanoma patients with brain metastases were treated with pembrolizumab in a prospective phase 2 trial, NCT02085070, and included in this secondary analysis. Patients had at least 1 untreated or progressive brain metastasis, 5 to 20 mm in size, without any associated neurologic symptoms. Local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy) was used to treat concerning lesions immediately before trial enrollment and was also allowed on trial in patients whose brain metastases were progressing, but who were otherwise deriving benefit. RESULTS: In total, 13 out of 23 patients (57%) received local therapy immediately before or during the trial-4 patients received local therapy before the trial owing to lesion size or location in sensitive areas; 6 during the trial because of tumor growth, hemorrhage, or radiation necrosis/cystic changes; and 3 both before and during the trial. Of the 10 patients who did not receive local therapy immediately before or during the trial, 8 patients (35%) did not later receive local therapy owing to rapid disease progression, and only 2 patients (9%) lived for 2 years without requiring any local therapy. CONCLUSIONS: Local therapy continues to play an important role in the management of melanoma patients with brain metastases being treated with immunotherapy. These patients should be closely monitored via serial brain imaging, with a multidisciplinary team involved in clinical decision making to ensure each patient's neurologic safety.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Qian JM, Yu JB, Mahajan A, et al. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. Int J Radiat Oncol Biol Phys. 2019. PMID: 31479702. doi:10.1016/j.ijrobp.2019.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。